Ebselen Derivatives for Mitochondrial Complex I Dysfunction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for mitochondrial illnesses, particularly those associated with mitochondrial complex I deficiencies, are limited by genetic and clinical diversity, and there is a need for causal and non-symptomatic therapeutic approaches.
Innovation Solution
The use of ebselen and its derivatives, such as ethaselen, which have inhibitory and antioxidant properties, to target mitochondrial malfunctions by administering them in pharmaceutical compositions, particularly through oral routes, to improve mitochondrial function and alleviate symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for mitochondrial illnesses are used, then symptomatic relief may be achieved, but the genetic and clinical diversity of the diseases prevents effective causal treatment
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of ebselen to create derivatives with specific functional groups (hydroxyl, carboxyl, amino, carbonyl) that can interact with different mitochondrial proteins. This structural parameter modification enables the treatment to adapt to various genetic and clinical presentations of mitochondrial diseases while maintaining core therapeutic activity.
Solution Approach 2:
The patent demonstrates universality by showing that ebselen and its derivatives can treat multiple types of mitochondrial illnesses ( Leigh syndrome, LHON, MELAS, Parkinson's disease, Alzheimer's disease) despite their genetic and clinical diversity. The compound acts on common mitochondrial dysfunction mechanisms across different disease types, providing a universal therapeutic approach.
2Reliability
If ebselen and derivatives are administered to treat mitochondrial illnesses, then mitochondrial function improves and symptoms are alleviated, but the complexity of developing and regulating new pharmacological treatments increases
Solution Approach 1:
The patent applies copying by using ebselen, a compound with known pharmacological properties and safety profile, as a template to create derivatives. Instead of developing entirely new compounds from scratch, the invention copies and modifies the successful ebselen structure, reducing development complexity while maintaining therapeutic efficacy.
Solution Approach 2:
The patent modifies the ebselen molecular structure by changing parameters such as adding functional groups (hydroxyl, carboxyl, amino, carbonyl) at specific positions. These parameter changes optimize the compound for different disease indications while leveraging the existing knowledge base of ebselen, thereby reducing the complexity of pharmaceutical development and regulation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Ebselen and its derivatives effectively treat mitochondrial illnesses by improving respiratory chain function and reducing symptoms, offering a potential cure or significant attenuation of the illness progression.
Implementation Method 1
ebselen, a drug currently used in particular in clinical trials for the treatment of hearing disorders, but also its derivatives, such as ethaselen, were active in the context of the treatment of illnesses associated with a mitochondrial malfunction, in particular illnesses of the mitochondrial respiratory chain
Implementation Method 2
The symptoms of mitochondrial illnesses may include: lactic acidosis, i.e. an accumulation of lactic acid in the blood or the urine
Data Source
AI summary
The invention relates to the use of ebselen or one of the derivatives thereof for treating pathologies or mitochondrial malfunctions in particular associated with complex I deficiencies.